Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 1
2019 1
2022 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

4 results

Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Long-Term Risk of Venous Thromboembolism in Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study.
Madenci AL, Weil BR, Liu Q, Murphy AJ, Gibson TM, Yasui Y, Leisenring WM, Howell RM, Tinkle CL, Nekhlyudov L, Diller LR, Armstrong GT, Oeffinger KC, Weldon CB. Madenci AL, et al. J Clin Oncol. 2018 Sep 14:JCO2018784595. doi: 10.1200/JCO.2018.78.4595. Online ahead of print. J Clin Oncol. 2018. PMID: 30216123
Purpose To estimate the incidence of late-occurring venous thromboembolism (VTE) among survivors of childhood cancer and to identify risk factors for VTE to facilitate diagnosis and prevention. ...Conclusion Childhood can
Purpose To estimate the incidence of late-occurring venous thromboembolism (VTE) among survivors of childhood
Burden of Long-Term Morbidity Borne by Survivors of Acute Myeloid Leukemia Treated With Blood or Marrow Transplantation: The Results of the BMT Survivor Study.
Armenian SH, Chen Y, Hageman L, Wu J, Landier W, Bosworth A, Francisco L, Schlichting E, Bhatia R, Salzman D, Wong FL, Weisdorf DJ, Forman SJ, Arora M, Bhatia S. Armenian SH, et al. J Clin Oncol. 2022 Oct 1;40(28):3278-3288. doi: 10.1200/JCO.21.02829. Epub 2022 Jun 22. J Clin Oncol. 2022. PMID: 35731989 Free PMC article.
The most prevalent conditions included subsequent neoplasms, diabetes, cataracts, venous thromboembolism, and joint replacement. Survivors were more likely to report poor general health (odds ratio [OR], 3.8; 95% CI, 2.8 to 5.1), activity limitation (O …
The most prevalent conditions included subsequent neoplasms, diabetes, cataracts, venous thromboembolism, and joint replacemen …
Venous Thromboembolism in Autologous Blood or Marrow Transplantation Survivors: A Report from the Blood or Marrow Transplant Survivor Study.
Gangaraju R, Chen Y, Hageman L, Wu J, Francisco L, Battles K, Kung M, Ness E, Parman M, Weisdorf DJ, Forman SJ, Arora M, Armenian SH, Bhatia S. Gangaraju R, et al. Biol Blood Marrow Transplant. 2019 Nov;25(11):2261-2266. doi: 10.1016/j.bbmt.2019.06.032. Epub 2019 Jul 3. Biol Blood Marrow Transplant. 2019. PMID: 31278995 Free PMC article. Clinical Trial.
Hemostatic complications are commonly encountered in blood or marrow transplantation (BMT) recipients, increasing their morbidity and mortality and are well described in the immediate post-transplantation period. The risk of venous thromboembolism (VTE …
Hemostatic complications are commonly encountered in blood or marrow transplantation (BMT) recipients, increasing their morbidity and mortal …
Risk of Cardiovascular Events and Lipid Profile Change in Patients with Breast Cancer Taking Aromatase Inhibitor: A Systematic Review and Meta-Analysis.
Yoo JJ, Jung EA, Kim Z, Kim BY. Yoo JJ, et al. Curr Oncol. 2023 Feb 2;30(2):1831-1843. doi: 10.3390/curroncol30020142. Curr Oncol. 2023. PMID: 36826103 Free PMC article.
Cardiovascular disease (CVD) is one of the most common comorbidities in breast cancer survivors. Recently, the target population and treatment period for aromatase inhibitor (AI) treatment in breast cancer patients has been expanding. ...Angina was the most c …
Cardiovascular disease (CVD) is one of the most common comorbidities in breast cancer survivors. Recently, the target populati …